Silk Road Medical (SILK)
(Delayed Data from NSDQ)
$27.50 USD
+0.22 (0.81%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $27.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
SILK 27.50 +0.22(0.81%)
Will SILK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SILK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SILK
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates
SILK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Edwards Lifesciences (EW) Q2 Earnings Match Estimates
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
Other News for SILK
BlackRock Health Sciences Term Trust Q2 2024 Commentary
Silk Road Medical ticks higher as HSR waiting period for Boston Scientific sale expires
Catalyst Watch: Apple's iPhone event, Oracle earnings, Google antitrust trial, and the August CPI print
SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific
Baron Discovery Fund Q2 2024 Shareholder Letter